Fox Chase Cancer Center
253
30
52
132
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
20.9%
53 terminated/withdrawn out of 253 trials
71.4%
-15.2% vs industry average
4%
11 trials in Phase 3/4
43%
57 of 132 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (253)
African Cancer Genome: GMD
Role: lead
Genetic Information for Families After Tumor Testing Study
Role: collaborator
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
Role: lead
Implementing the NYU Electronic Patient Visit Assessment (ePVA) for Head and Neck Cancer In Rural and Urban Populations
Role: collaborator
PET-CT in Determining the Radioembolization Dose Delivered to Patients With Liver Metastasis, Primary Liver Cancer, or Biliary Cancer
Role: lead
Mycophenolate Mofetil w/ Prednisone for Immune Related Hepatitis From Checkpoint Inhibitor Therapy
Role: lead
Engaging M-health for Symptom Monitoring and Health Promotion for Women on Endocrine Therapy for Breast Cancer (EmSHAPE)
Role: collaborator
Prehabilitation in High-risk Oncologic Surgery
Role: lead
Communication About Sexual Health in Gynecologic Cancer
Role: lead
Penn Medicine Biobank Return of Results Program
Role: collaborator
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
Role: lead
Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer
Role: lead
Pulse-low-dose Rate (PLDR) Radiation in Pancreatic Cancer
Role: lead
Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx Cancer
Role: lead
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
Role: lead
Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC
Role: lead
Iron Replacement to Reduce Anemia During Neoadjuvant Chemotherapy
Role: lead
Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma
Role: lead
Organ Preservation in Early Rectal Cancer Patients
Role: lead
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Role: lead